基于循环肿瘤细胞的前列腺特异性膜抗原（PSMA）和前列腺特异抗原（PSA）表达作为前列腺癌的预测和预后工具 - Suppr

Suppr

超能文献

Circulating tumor cell-based PSMA and PSA expression as a predictive and prognostic tool in prostate cancer.

作者信息

Vlachostergios Panagiotis J

机构信息

Department of Medical Oncology, IASO Thessalias Hospital, Larissa, Greece.

Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

出版信息

Transl Cancer Res. 2025 Mar 30;14(3):1511-1515. doi: 10.21037/tcr-2024-2512. Epub 2025 Mar 24.

DOI:10.21037/tcr-2024-2512

PMID:40224993

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11985174/

Abstract

摘要

相似文献

Circulating tumor cell-based PSMA and PSA expression as a predictive and prognostic tool in prostate cancer.基于循环肿瘤细胞的前列腺特异性膜抗原（PSMA）和前列腺特异抗原（PSA）表达作为前列腺癌的预测和预后工具

Transl Cancer Res. 2025 Mar 30;14(3):1511-1515. doi: 10.21037/tcr-2024-2512. Epub 2025 Mar 24.

Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.循环肿瘤细胞表达的前列腺特异性膜抗原和前列腺特异性抗原转录本在前列腺癌不同阶段的影响。

Clin Cancer Res. 2024 May 1;30(9):1788-1800. doi: 10.1158/1078-0432.CCR-23-3083.

Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.通过将 VTX-1 CTC 分离系统与 QIAGEN AdnaTest 相结合，检测转移性去势抵抗性前列腺癌（mCRPC）患者的循环肿瘤细胞（CTC）和血浆外泌体衍生 cfRNA 中的雄激素受体（AR）、AR 变体 7（AR-V7）、前列腺特异性膜抗原（PSMA）和前列腺特异性抗原（PSA）基因表达。

BMC Cancer. 2024 Apr 16;24(1):482. doi: 10.1186/s12885-024-12139-3.

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.循环肿瘤细胞中的前列腺特异性膜抗原是去势抵抗性前列腺癌的新的预后不良标志物。

PLoS One. 2020 Jan 27;15(1):e0226219. doi: 10.1371/journal.pone.0226219. eCollection 2020.

Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.表达前列腺特异性膜抗原（PSMA）的循环肿瘤细胞表明原发性非转移性三阴性乳腺癌的预后较差。

Front Oncol. 2020 Sep 3;10:1658. doi: 10.3389/fonc.2020.01658. eCollection 2020.

Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.Ad5/35E1aPSESE4：一种利用由前列腺特异性抗原（PSA）/前列腺特异性膜抗原（PSMA）转录调控元件控制的具有复制能力的腺病毒标记循环前列腺肿瘤细胞的新方法。

Cancer Lett. 2016 Mar 1;372(1):57-64. doi: 10.1016/j.canlet.2015.12.018. Epub 2015 Dec 23.

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving Lu-PSMA-617 Radioligand Therapy.转移性去势抵抗性前列腺癌患者接受 Lu-PSMA-617 放射性配体治疗时循环肿瘤细胞的分子分析。

Theranostics. 2020 Jun 18;10(17):7645-7655. doi: 10.7150/thno.44556. eCollection 2020.

A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients.基于PSMA PET/CT的可视化全身肿瘤负荷分类，用于预测转移性激素敏感性前列腺癌患者对新型雄激素受体信号抑制剂的反应。

Eur J Nucl Med Mol Imaging. 2025 Apr 25. doi: 10.1007/s00259-025-07300-4.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.BIND-014 治疗转移性去势抵抗性前列腺癌的安全性和疗效：一项针对前列腺特异性膜抗原的紫杉醇纳米颗粒的 2 期临床试验。

JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168.

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.一项关于在接受晚期前列腺癌治疗的男性中前列腺特异性膜抗原（PSMA）动态变化的初步研究。

Prostate. 2019 Oct;79(14):1597-1603. doi: 10.1002/pros.23883. Epub 2019 Jul 30.

本文引用的文献

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer.循环肿瘤细胞的多标志物分析在局限性中高危和转移性前列腺癌中的应用。

Clin Exp Metastasis. 2024 Dec;41(6):937-945. doi: 10.1007/s10585-024-10313-2. Epub 2024 Sep 21.

Metastatic hormone-naïve prostate cancer: a distinct biological entity.转移性去势敏感前列腺癌：一种独特的生物学实体。

Trends Cancer. 2024 Sep;10(9):825-841. doi: 10.1016/j.trecan.2024.06.005. Epub 2024 Jul 23.

Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.前列腺癌中前列腺特异性膜抗原（PSMA）表达、调控及异质性的生物学决定因素

Nat Rev Urol. 2025 Jan;22(1):26-45. doi: 10.1038/s41585-024-00900-z. Epub 2024 Jul 8.

BMC Cancer. 2024 Apr 16;24(1):482. doi: 10.1186/s12885-024-12139-3.

Clin Cancer Res. 2024 May 1;30(9):1788-1800. doi: 10.1158/1078-0432.CCR-23-3083.

Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer.通过基于血液的液体活检检测前列腺癌循环肿瘤细胞上的PSMA表达。

J Circ Biomark. 2024 Feb 21;13:1-6. doi: 10.33393/jcb.2024.2636. eCollection 2024 Jan-Dec.

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.循环肿瘤细胞 HOXB13 RNA 检测对接受阿比特龙或恩杂鲁胺治疗的转移性去势抵抗性前列腺癌（mCRPC）男性的影响。

Clin Cancer Res. 2024 Mar 15;30(6):1152-1159. doi: 10.1158/1078-0432.CCR-23-3017.

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.PSMA 阳性循环肿瘤细胞检测与阿比特龙或恩扎鲁胺治疗转移性去势抵抗性前列腺癌患者的结局。

Clin Cancer Res. 2023 May 15;29(10):1929-1937. doi: 10.1158/1078-0432.CCR-22-3233.

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.一种临床级别的液体生物标志物可检测前列腺癌中的神经内分泌分化。

J Clin Invest. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858.

Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.欧洲及全球基于血清前列腺特异性抗原的前列腺癌早期检测：过去、现在与未来

Nat Rev Urol. 2022 Sep;19(9):562-572. doi: 10.1038/s41585-022-00638-6. Epub 2022 Aug 16.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验